The following is a summary of “Association between incretin-based drugs and risk of cholangiocarcinoma among patients with ...

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

Researchers at Mount Sinai have shown that a combination of two drugs—harmine and a glucagon-like peptide 1 receptor agonist (GLP-1RA)—can enhance the regeneration of insulin-producing ...